切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2019, Vol. 13 ›› Issue (06) : 618 -621. doi: 10.3877/cma.j.issn.1674-3946.2019.06.023.

所属专题: 文献

论著

联合血管切除重建的胰腺癌根治术对胰腺癌患者并发症发生率及生存质量的影响
刘婷1, 张灿1, 谢萍1,()   
  1. 1. 225001 江苏扬州,江苏省苏北人民医院肝胆胰中心
  • 收稿日期:2019-03-04 出版日期:2019-12-26
  • 通信作者: 谢萍

Influence of radical operation for pancreatic cancer combined with vascular resection and reconstruction on the incidence of complications and quality of life in patients with pancreatic cancer

Ting Liu1, Can Zhang1, Ping Xie1,()   

  1. 1. Hepatic Biliary Pancreatic Center, Jiangsu Province North Jiangsu People’s Hospital, 225001
  • Received:2019-03-04 Published:2019-12-26
  • Corresponding author: Ping Xie
  • About author:
    Correspondence author: Xe Ping, Email:
引用本文:

刘婷, 张灿, 谢萍. 联合血管切除重建的胰腺癌根治术对胰腺癌患者并发症发生率及生存质量的影响[J/OL]. 中华普外科手术学杂志(电子版), 2019, 13(06): 618-621.

Ting Liu, Can Zhang, Ping Xie. Influence of radical operation for pancreatic cancer combined with vascular resection and reconstruction on the incidence of complications and quality of life in patients with pancreatic cancer[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2019, 13(06): 618-621.

目的

评价联合血管切除重建的胰腺癌根治术对胰腺癌患者并发症发生率及生存质量的影响。

方法

回顾性分析2015年5月至2018年5月接受胰腺癌根治术的145例胰腺癌患者临床资料,依据术中是否应用血管切除重建分为A组(无血管切除,n=77)、V组(静脉切除重建,n=58)、O组(动脉切除重建,n=10)三组。采用SPSS 24.0软件进行数据处理,手术相关指标、生存质量及生存时间等计量资料以(±s)表示,组间比较t检验,多组间比较通过单因素方差分析;并发症等组间比较通过χ2检验。检验水准α=0.05,P<0.05为差异具有统计学意义。

结果

O组手术时间、术中出血量、输血率及并发症发生率>V组>A组(P<0.05);三组术后6个月健康状况调查简表(SF-36)比术前升高(P<0.05),但三组相比差异无统计学意义(P>0.05);三组术中均无死亡病例,A组、V组及O组中位生存时间分别为(16.2±1.5)个月、(15.3±1.2)个月、(14.2±1.9)个月,差异无统计学意义(P>0.05)。

结论

胰腺癌根治术术中联合动、静脉切除均存在手术时间长、出血量多、并发症发生率高等不足,但可获得与无血管切除重建相近的生存时间、预后及生存质量;故在符合手术指征下应推荐无血管切除重建。

Objective

To evaluate the influence of radical operation for pancreatic cancer combined with vascular resection and reconstruction on the incidence of complications and quality of life in patients with pancreatic cancer.

Methods

The clinical data of 145 pancreatic cancer patients with radical operation for pancreatic cancer from May 2015 to May 2018 were retrospectively analyzed. According to the intraoperative vascular resection and reconstruction, all patients were divided into A group (non-vascular resection, n=77), V group (venous resection and reconstruction, n=58) and O group (arterial resection and reconstruction, n=10). SPSS 24.0 software was used for data processing. The surgical indexes, quality of life and survival time were expressed as (±s). The t test was adopted between groups, the one-way analysis of variance was adopted among groups; The χ2 test was adopted to compare the complications among groups. α=0.05, P<0.05 were considered statistically significant.

Results

The operation time, intraoperative bleeding volume, blood transfusion volume and the incidence of complications in O group were higher than those in V group and A group (P<0.05); After surgery for 6 months, the scores of short form-36 health status questionnaire (SF-36) in the three groups were higher than those before surgery (P<0.05), but there was no statistical difference among the three groups (P>0.05); There was no dead cases in the three groups during surgery, the median survival time of A group, V and O group were (16.2±1.5) months, (15.3±1.2) months, (14.2±1.9) months, and the difference was not statistically significant (P>0.05).

Conclusion

Radical operation for pancreatic cancer combined with arterial and venous resection has shortcomings such as long operation time, high bleeding volume and high incidence of complications, but it can obtain similar survival time, prognosis and quality of life with non-vascular resection and reconstruction. Therefore, vascular resection and reconstruction can be recommended in accordance with the indications for surgery.

表1 145例胰腺癌根治术患者不同血管重建方式三组患者基本资料比较[(±s),例]
表2 145例胰腺癌根治术患者不同血管重建方式三组手术相关指标对比(±s)
表3 145例胰腺癌根治术患者不同血管重建方式三组并发症发生率对比(例)
表4 145例胰腺癌根治术患者不同血管重建方式三组SF-36评分对比[(±s),分]
[1]
杨永超,李宜雄.胰腺癌外科治疗的历史和现状[J].中国普通外科杂志,2018,27(3): 269-283.
[2]
Nagakawa Y, Hosokawa Y, Sahara Y,et al. Approaching the superior mesenteric artery from the right side using the proximal-dorsal jejunal vein preisolation method during laparoscopic pancreaticoduodenectomy[J].Surg Endosc, 2018,32(9): 4044-4051.
[3]
匡天佐,袁荣发,胡昌昌,等.联合血管切除重建的胰腺癌根治术:附12例报告[J].中国普通外科杂志,2016,25(9): 1242-1246.
[4]
黄斌,陆才德,裘丰,等.联合血管切除重建在胰腺癌根治术中的安全性及价值[J].中华外科杂志,2016,54(1): 56-62.
[5]
中国抗癌协会胰腺癌专业委员会.胰腺癌综合诊治指南(2018版) [J].中华外科杂志,2018,56(7): 481-494.
[6]
中华医学会外科学分会胰腺外科学组,中华外科杂志编辑部.胰腺术后外科常见并发症预防及治疗的专家共识(2010)[J].中华外科杂志,2010,48(18): 1365-1368.
[7]
Jang ES, Kim YS, Kim KA,et al. Factors Associated with Health-Related Quality of Life in Korean Patients with Chronic Hepatitis C Infection Using the SF-36 and EQ-5D[J]. Gut Liver, 2018, 12(4): 440-448.
[8]
Brown DR, Lanciano R, Heal C,et al. The effect of whole-brain radiation (WBI) and Karnofsky performance status (KPS) on survival of patients receiving stereotactic radiosurgery (SRS) for second brain metastatic event[J]. J Radiat Oncol, 2017, 6(1): 31-37.
[9]
庄岩,田孝东,高红桥,等.腹腔镜胰十二指肠切除术的难点与争议[J/CD].中华普外科手术学杂志(电子版),2018,12(4): 271-274.
[10]
勾善淼,吴河水.胰腺癌根治术淋巴结清扫范围的发展历程[J].临床肝胆病杂志,2017,33(1): 57-60.
[11]
Inoue Y, Saiura A, Takahashi Y. A Novel Classification and Staged Approach for Dissection Along the Celiac and Hepatic Artery During Pancreaticoduodenectomy[J]. World J Surg, 2018,42(9): 2968-2968.
[12]
方向,石刚,麦刚,等.联合血管切除重建在胰腺癌根治术中的临床价值[J].重庆医学,2017,46(18): 2509-2511.
[13]
贾长库,徐孙兵,刘凌,等.联合动脉切除重建的胰腺癌根治性切除2例[J].中国现代医学杂志,2018,28(12): 123-125.
[14]
蒋奎荣,吴鹏飞,苗毅.联合门静脉-肠系膜上静脉切除的胰腺癌根治术[J].中华消化外科杂志,2018,17(7): 692-696.
[15]
Inoue Y, Saiura A, Takahashi Y. A Novel Classification and Staged Approach for Dissection Along the Celiac and Hepatic Artery During Pancreaticoduodenectomy[J]. World J Surg, 2018,42(9): 2963-2967.
[16]
姚波,谢亮,张光全.胰腺癌根治术联合门静脉切除治疗门静脉受累胰腺癌的近期疗效及远期预后分析[J].解放军医药杂志,2018,30(12): 23-26.
[17]
房炯泽,陆才德,黄斌,等.联合门静脉/肠系膜上静脉切除重建的胰十二指肠切除术治疗胰腺癌疗效分析[J].现代实用医学,2016,28(2): 167-170.
[18]
王伟林.联合门静脉/肠系膜上静脉切除的胰腺癌根治术[J].中华普通外科杂志,2017,32(9): 725-727.
[1] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[2] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[5] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[6] 许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[7] 康婵娟, 张海涛, 翟静洁. 胰管支架置入术治疗急性胆源性胰腺炎的效果及对患者肝功能、炎症因子水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 667-670.
[8] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[9] 李澄清, 郭文毅, 王磊. 腹腔镜保留脾脏胰体尾切除术:微创胰腺外科的合理决策[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 620-624.
[10] 郭诗翔, 谭明达, 王槐志. 胰头癌淋巴结清扫再思考[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 625-628.
[11] 张昊, 潘卫东. 胰腺癌新辅助化疗后可切除性评估现状及进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 629-633.
[12] 周倜, 吴嘉, 韩方, 徐林伟, 张宇华. 新辅助治疗时代胰腺癌淋巴结清扫研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 634-639.
[13] 王军华, 王锐炫. 胰腺癌新辅助化疗现状和治疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 640-643.
[14] 魏妙艳, 徐近. 合并远处转移胰腺癌系统性治疗的梳理和展望[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 644-650.
[15] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
阅读次数
全文


摘要